フォロー
Lihong Liu
タイトル
引用先
引用先
Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ...
Nature 593 (7857), 130-135, 2021
24762021
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
L Liu, P Wang, MS Nair, J Yu, M Rapp, Q Wang, Y Luo, JFW Chan, V Sahi, ...
Nature 584 (7821), 450-456, 2020
15112020
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu, Y Luo, H Chu, Y Huang, ...
Nature 602 (7898), 676-681, 2022
12992022
Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization
P Wang, RG Casner, MS Nair, M Wang, J Yu, G Cerutti, L Liu, PD Kwong, ...
Cell host & microbe 29 (5), 747-751. e4, 2021
9902021
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
S Iketani, L Liu, Y Guo, L Liu, JFW Chan, Y Huang, M Wang, Y Luo, J Yu, ...
Nature 604 (7906), 553-556, 2022
8452022
Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5
Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri, M Wang, J Yu, ...
Nature 608 (7923), 603-608, 2022
7932022
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Q Wang, S Iketani, Z Li, L Liu, Y Guo, Y Huang, AD Bowen, M Liu, ...
Cell 186 (2), 279-286. e8, 2023
7582023
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
G Cerutti, Y Guo, T Zhou, J Gorman, M Lee, M Rapp, ER Reddem, J Yu, ...
Cell host & microbe 29 (5), 819-833. e7, 2021
5202021
Antibody response to omicron BA. 4–BA. 5 bivalent booster
Q Wang, A Bowen, R Valdez, C Gherasim, A Gordon, L Liu, DD Ho
New England Journal of Medicine 388 (6), 567-569, 2023
214*2023
Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles
M Lu, PD Uchil, W Li, D Zheng, DS Terry, J Gorman, W Shi, B Zhang, ...
Cell host & microbe 28 (6), 880-891. e8, 2020
1842020
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
P Wang, L Liu, MS Nair, MT Yin, Y Luo, Q Wang, T Yuan, K Mori, AG Solis, ...
Emerging microbes & infections 9 (1), 2091-2093, 2020
1422020
Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike
Q Wang, Y Guo, L Liu, LT Schwanz, Z Li, MS Nair, J Ho, RM Zhang, ...
Nature 624 (7992), 639-644, 2023
1412023
A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike
B Dadonaite, KHD Crawford, CE Radford, AG Farrell, CY Timothy, ...
Cell 186 (6), 1263-1278. e20, 2023
1142023
Cryo-EM structure of the SARS-CoV-2 Omicron spike
G Cerutti, Y Guo, L Liu, L Liu, Z Zhang, Y Luo, Y Huang, HH Wang, DD Ho, ...
Cell reports 38 (9), 2022
912022
Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA. 2.75
Q Wang, S Iketani, Z Li, Y Guo, AY Yeh, M Liu, J Yu, Z Sheng, Y Huang, ...
Cell host & microbe 30 (11), 1512-1517. e4, 2022
902022
XBB. 1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN. 1
Q Wang, Y Guo, A Bowen, IA Mellis, R Valdez, C Gherasim, A Gordon, ...
Cell host & microbe 32 (3), 315-321. e3, 2024
882024
Resistance of SARS-CoV-2 omicron subvariant BA. 4.6 to antibody neutralisation
Q Wang, Z Li, J Ho, Y Guo, AY Yeh, H Mohri, M Liu, M Wang, J Yu, ...
The Lancet Infectious Diseases 22 (12), 1666-1668, 2022
742022
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG. 5.1 and XBC. 1.6
Q Wang, Y Guo, RM Zhang, J Ho, H Mohri, R Valdez, DM Manthei, ...
The Lancet Infectious Diseases 23 (10), e397-e398, 2023
702023
Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes
T Zhou, IT Teng, AS Olia, G Cerutti, J Gorman, A Nazzari, W Shi, ...
Cell reports 33 (4), 2020
702020
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
M Rapp, Y Guo, ER Reddem, J Yu, L Liu, P Wang, G Cerutti, P Katsamba, ...
Cell Reports 35 (1), 2021
682021
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20